Expert Review of Pharmacoeconomics & Outcomes Research
ISSN:1473-7167

Expert Review of Pharmacoeconomics & Outcomes Research

EXPERT REV PHARM OUT
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:较慢,6-12周
新锐分区:医学4区
年发文量:106
影响因子:1.5
JCR分区:Q3

基本信息

《 药物 经济 学 和 结果 研究 专家 评论 》 ( ISSN 1473 - 7167 ) 提供 了 与 药物 临床 使用 和 治疗 方法 相关 的 成本 效益 和 药物 经济 学 问题 的 专家 评论 。覆盖 范围 包括 药物 经济 学 和 生活 质量 研究 、 治疗 结果 、 循 证 医学 和 成本 效益 研究 。所有 文章 均 经过 严格 的 同行 评审 。该 杂志 采用 独特 的 专家 评审 文章 格式 , 提供 了 一 个 关键 技术 领域 、 研究 或 临床 实践 的 当前 思想 的 完整 概述 , 并 通过 以下 章节 进行 了 补充 :专家 意见 - 对 文章 中 数据 的 个人 观点 , 对 未来 可能 重要 的 发展 的 讨论 , 以及 随着 进一步 研究 产生 更 详细 的 结果 而 可能 变得 令 人 兴奋 的 研究 途径 文章 要点 - 作者 最 关键 观点 的 执行 摘要 。
1473-7167SCIE/SSCI/Scopus收录
1.5
2.2
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
4区
HEALTH POLICY & SERVICES 卫生政策与服务
4区
PHARMACOLOGY & PHARMACY 药学
4区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:HEALTH CARE SCIENCES & SERVICES
SCIE
Q3
136/188
学科:HEALTH POLICY & SERVICES
SSCI
Q4
97/125
学科:PHARMACOLOGY & PHARMACY
SCIE
Q4
267/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:HEALTH CARE SCIENCES & SERVICES
SCIE
Q3
141/188
学科:HEALTH POLICY & SERVICES
SSCI
Q4
102/125
学科:PHARMACOLOGY & PHARMACY
SCIE
Q3
236/353
41
106
2%较易较慢,6-12周-HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY
6.7%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
71.70%18.48%-
CiteScore:3.80
SJR:0.585
SNIP:0.662
学科类别分区排名百分位
大类:Medicine
小类:Health Policy
Q2
120 / 320
大类:Medicine
小类:Pharmacology (medical)
Q2
135 / 275

期刊高被引文献

Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1575730
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2018.1518134
Cognitive behavior therapy for health anxiety: systematic review and meta-analysis of clinical efficacy and health economic outcomes
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1703182
The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2020.1678385
Cost burden of diffuse large B-cell lymphoma
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1680288
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2017.1347041
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1647104
Review of studies reporting actual prices for medicines
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1552137
Cross-national drug price comparisons with economic weights in external reference pricing in Germany
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1527221
The evolving role of patient advocates in rare cancers: opportunities and challenges
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1526083
How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1702524
Reviewing estimates of the burden in disability-adjusted life years (DALYs) of tick-borne encephalitis in Slovenia
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1573677
Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1554437
Analysis of prevalence, risk factors, and potential costs of unnecessary drug therapy in patients with chronic diseases at the outpatient setting
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1612243
Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1667232
Effects of economic and health policies on the consumption of antibiotics in a Spanish region
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1647105
Review of health economic analyses in atopic dermatitis: how diverse is the literature?
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1549491
Direct cost of Parkinson’s disease in a health system with high judicialization: evidence from Colombia
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2020.1681266
Disease activity and sleep quality in rheumatoid arthritis: a deeper look into the relationship
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2020.1677156
Adding two culture-specific ‘bolt-on’ dimensions on the Thai version of EQ-5D-5L: an exploratory study in patients with diabetes
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1525294
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2018.1518135
Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1541404
Evaluation of Jordanian Healthcare Providers’ Knowledge, Attitudes, and Practice Patterns towards Probiotics
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1609354
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1527220
Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1626720
Quality of life and costs of patients prior to colorectal surgery
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1628641
Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1592680
Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1662302
Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1629291
Breast Cancer Quality of Life and Health-state Utility at a Brazilian Reference Public Cancer Center
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1621752
Achieving cost-efficient management of drug supply via economic order quantity and minimum-maximum stock level
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1633308
Value-based medicine and palliative care: how do they converge?
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1651645
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1635014
Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1629905
A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1644169
Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1615886
The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2020.1688146
Systematic literature review on the economic, humanistic, and societal burden of heart failure in children and adolescents
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1579645
Pharmaceutical expenditure and total health-care expenditure in OECD countries and China: bidirectional Granger causality on the basis of health level.
来源期刊:Expert review of pharmacoeconomics & outcomes researchDOI:10.1080/14737167.2019.1605292
Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1680289
Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1702879
The direct and indirect costs of epilepsy in Poland estimates for 2014–2016 years
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1533817
Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1702525
Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1702523
A systematic review and cost analysis of repeat colonoscopies due to inadequate bowel cleansing in five European countries
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1597709
The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1650024
Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1580572
Evaluating intensive care unit medication charges in a teaching hospital in Jordan
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1571413
Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2019.1582334
Intrinsic properties of medical devices: considerations for economic evaluation
来源期刊:Expert Review of Pharmacoeconomics & Outcomes ResearchDOI:10.1080/14737167.2020.1693268

相关文章

2026年3月发布(新锐分区)
大类学科小类学科Top期刊综述期刊
医学4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
4区
HEALTH POLICY & SERVICES 卫生政策与服务
4区
PHARMACOLOGY & PHARMACY 药学
4区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
4区
HEALTH POLICY & SERVICES 卫生政策与服务
4区
PHARMACOLOGY & PHARMACY 药学
4区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
4区
HEALTH POLICY & SERVICES 卫生政策与服务
4区
PHARMACOLOGY & PHARMACY 药学
4区